Johnson & Johnson (JNJ)
160.65
+1.01
(+0.63%)
USD |
NYSE |
Jul 26, 16:00
160.50
-0.15
(-0.09%)
After-Hours: 20:00
Johnson & Johnson Revenue (TTM): 86.58B for June 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
June 30, 2024 | 86.58B |
March 31, 2024 | 89.66B |
December 31, 2023 | 89.17B |
September 30, 2023 | 87.71B |
June 30, 2023 | 86.36B |
March 31, 2023 | 84.85B |
December 31, 2022 | 87.38B |
September 30, 2022 | 77.21B |
June 30, 2022 | 80.55B |
March 31, 2022 | 79.84B |
December 31, 2021 | 78.74B |
September 30, 2021 | 91.45B |
June 30, 2021 | 89.19B |
March 31, 2021 | 84.21B |
December 31, 2020 | 82.58B |
September 30, 2020 | 80.86B |
June 30, 2020 | 80.50B |
March 31, 2020 | 82.73B |
December 31, 2019 | 82.06B |
September 30, 2019 | 81.71B |
June 30, 2019 | 81.32B |
March 31, 2019 | 81.59B |
December 31, 2018 | 81.58B |
September 30, 2018 | 81.38B |
June 30, 2018 | 80.68B |
Date | Value |
---|---|
March 31, 2018 | 78.69B |
December 31, 2017 | 76.45B |
September 30, 2017 | 74.36B |
June 30, 2017 | 72.53B |
March 31, 2017 | 72.17B |
December 31, 2016 | 71.89B |
September 30, 2016 | 71.60B |
June 30, 2016 | 70.88B |
March 31, 2016 | 70.18B |
December 31, 2015 | 70.07B |
September 30, 2015 | 70.52B |
June 30, 2015 | 71.88B |
March 31, 2015 | 73.59B |
December 31, 2014 | 74.33B |
September 30, 2014 | 74.43B |
June 30, 2014 | 73.54B |
March 31, 2014 | 71.92B |
December 31, 2013 | 71.31B |
September 30, 2013 | 70.52B |
June 30, 2013 | 69.99B |
March 31, 2013 | 68.59B |
December 31, 2012 | 67.22B |
September 30, 2012 | 65.92B |
June 30, 2012 | 64.87B |
March 31, 2012 | 65.00B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
77.21B
Minimum
Sep 2022
91.45B
Maximum
Sep 2021
84.17B
Average
83.47B
Median
Revenue (TTM) Benchmarks
Eli Lilly and Co | 35.93B |
Merck & Co Inc | 61.40B |
Pfizer Inc | 55.09B |
AbbVie Inc | 54.40B |
Bristol-Myers Squibb Co | 45.53B |